Efficacy and Safety of Hou Gu Mi Xi on Spleen Qi Deficiency in Patients with Nonorganic Gastrointestinal Disorders: Protocol for a Multicenter, Randomized, Placebo-Controlled Trial

Xiaofan Chen, Heyun Nie, Wenjun Liu, Xu Zhou, Jianhua Nie, Bin Xie, Dongping Chen, Yiping Jiang, Kunhe Zhang, Ying Fu, Deping Yang, Yan Xiong, Zhangyang Zhao, Xin Sun, Weifeng Zhu, Xiaofan Chen, Heyun Nie, Wenjun Liu, Xu Zhou, Jianhua Nie, Bin Xie, Dongping Chen, Yiping Jiang, Kunhe Zhang, Ying Fu, Deping Yang, Yan Xiong, Zhangyang Zhao, Xin Sun, Weifeng Zhu

Abstract

Background: There is a worldwide epidemic of nonorganic gastrointestinal disorders (NOGDs), which are a class of disorders that cause various discomforts and ultimately progress into organic gastrointestinal diseases. Because of the unsatisfactory efficacy of Western medical treatments, traditional Chinese medicine (TCM) is becoming a promising complementary and alternative treatment to manage NOGDs.

Objectives: To investigate the efficacy and safety of Hou Gu Mi Xi (HGMX), a newly developed dietary TCM formula, on the syndrome of spleen qi deficiency (SQD) in patients with NOGDs.

Methods/design: This study is a multicenter, randomized, double-blinded, parallel, and placebo-controlled trial that will last for 2 years. All qualified subjects with NOGDs and SQD will be included. The study population will be divided into the HGMX and placebo groups. To assess the efficacy of HGMX, we will mainly focus on changes in SQD symptoms scored by a Spleen Qi Deficiency Symptoms Grading and Quantifying Scale and evaluate changes in gastrin-17, the negative Helicobacter pylori conversion rate, body weight, body mass index, and gastroscopy findings. The safety of HGMX will be assessed by recording adverse events (AEs), severe AEs, treatment-related AEs and withdrawal due to AEs.

Discussion: This trial is part of our study series that intends to validate the potential of HGMX in the management of chronic gastrointestinal diseases. This series of RCTs is the first committed to the evaluation of a dietary TCM formula and will hopefully establish an evidence-based clinical research model for dietary TCM formulas.

Ethics: The protocol was approved by Ethics Committee of five research hospitals and was registered in Clinicaltrials.gov (NCT03019042).

Figures

Figure 1
Figure 1
Overall design of the study.

References

    1. Everhart J. E., Ruhl C. E. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology. 2009;136(2):376–386. doi: 10.1053/j.gastro.2008.12.015.
    1. Peery A. F., Dellon E. S., Lund J., et al. Burden of gastrointestinal disease in the United States: update. Gastroenterology. 2012;143(5):1179–1187.
    1. Qin J. M., Zhang Y. C., Zhang L. F. Chronic disease prevalence and disease burden analysis of typical urban residents. Chinese Journal of Public Health. 2014;30(1):5–7.
    1. Busuttil R. A., Boussioutas A. Intestinal metaplasia: A premalignant lesion involved in gastric carcinogenesis. Journal of Gastroenterology and Hepatology. 2009;24(2):193–201. doi: 10.1111/j.1440-1746.2008.05774.x.
    1. Campana D., Ravizza D., Ferolla P., et al. Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine Journal. 2016;51(1):131–139. doi: 10.1007/s12020-015-0584-z.
    1. Drossman D. A. Functional gastrointestinal disorders: History, pathophysiology, clinical features, and Rome IV. Gastroenterology. 2016;150(6):1262.e1262–1279.e1262. doi: 10.1053/j.gastro.2016.02.032.
    1. Digestive System Disease Professional Committee in Integrated Traditional Chinese and Western Medicine Association in China. Consensus on integrated traditional Chinese and Western medicine in the treatment of chronic gastritis (Tianjin, 2011) Chinese Journal of Integrated Traditional and Western Medicine. 2011;32(6):738–743.
    1. Barbara G., Feinle-Bisset C., Ghoshal U. C., et al. The intestinal microenvironment and functional gastrointestinal disorders. Gastroenterology. 2016;150(6):1305–1318. doi: 10.1053/j.gastro.2016.02.028.
    1. Wang Y. T., Kwok K. F. V., Tan S. M., et al. Comprehensive psychological intervention to improve outcome in functional gastrointestinal disorder: A cohort study. Singapore Medical Journal. 2015;56(7):385–392. doi: 10.11622/smedj.2015109.
    1. Wei S.-C., Chang T.-A., Chao T.-H., et al. Management of ulcerative colitis in Taiwan: Consensus guideline of the Taiwan Society of inflammatory bowel disease. Intestinal Research. 2017;15(3):266–284. doi: 10.5217/ir.2017.15.3.266.
    1. Spiller R., Aziz Q., Creed F., et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007;56(12):1770–1798.
    1. Hou Z. K., Li M., Xie D., Liu F. B. Traditional Chinese medicine syndrome distribution and neuroendocrine mechanisms of irritable bowel syndrome: cross-sectional study. China Journal of Chinese Materia Medica. 2016;41(7):1325–1337.
    1. Zheng X. Clinical Guideline of New Drugs for Traditional Chinese Medicine. Beijing, China: Medicine Science and Technology Press of China; 1993.
    1. Tai Ping Hui Min He Ji Ju. Tai Ping Hui Min He Ji Ju Fang, Juan 3 (Imperial Grace Formulary of the Tai Ping Era, Volume 3). Song Dynasty (1102 AD)
    1. Wang M., Yu M., Wang C., Wang C. X. Meta-analysis of Shenling Baizhu San for Treatment of Functional Dyspepsia. Chinese Journal of Health Statistics. 2014;31(6):939–942.
    1. Chan A. W., Tetzlaff J. M., Altman D. G., et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Annals of Internal Medicine. 2013;158(3):200–207. doi: 10.7326/0003-4819-158-3-201302050-00583.
    1. Edwards I. R., Aronson J. K. Adverse drug reactions: definitions, diagnosis, and management. The Lancet. 2000;356(9237):1255–1259. doi: 10.1016/s0140-6736(00)02799-9.
    1. Zhong B. How to calculate sample size in randomized controlled trial? Journal of Thoracic Disease. 2009;1(1):51–54.
    1. Jennison C., Turnbull B. W. Group Sequential Methods with Applications to Clinical Trials. Chapman and Hall/CRC; 1999.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi